Chroma Medicine
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $135M
Overview
Developing single-dose epigenetic medicines to turn genes on or off without cutting DNA.
Genetics & Genomics
Technology Platform
A modular epigenetic editing platform designed to precisely silence or activate genes without cutting the DNA double helix.
Funding History
1Total raised:$135M
Venture$135M
Opportunities
Potential to treat a vast array of diseases by reprogramming gene expression with a favorable safety profile compared to gene cutting.
Risk Factors
Unproven clinical durability and delivery of epigenetic editors, alongside a nascent regulatory pathway for such therapies.
Competitive Landscape
Faces competition from established CRISPR gene editing firms (e.g., CRISPR Therapeutics) and other epigenetic editing startups like Tune Therapeutics.